AveloMask Pneumonia Data Presented at ESCMID Global 2026 in Munich
- Apr 29
- 1 min read
April 29, 2026. Avelo AG is pleased to share that Prof. Dr. Michael Osthoff from University Hospital Basel presented real-world clinical results for AveloMask at ESCMID Global 2026 in Munich, one of the world's leading conferences in clinical microbiology and infectious diseases.
The data, generated in a prospective two-center study (AeroCAP) with 63 adults with confirmed lower respiratory tract infections (LRTIs), showed that AveloMask breath aerosol PCR:
Detected the dominant LRTI pathogen in 85% of patients, with a specificity of 100%
Provides a practical sampling option when sputum is unavailable
Is well-tolerated by patients with pneumonia
Is compatible with commercial multiplex PCR platforms
The findings reinforce the value of non-invasive breath sampling for patients who cannot produce sputum, a group that is frequently excluded from conventional diagnostics. A full manuscript is in preparation. Stay tuned.
Watch the recorded presentation and/or download the poster below:
About Avelo
Avelo AG, the Swiss breath sampling company, aims to revolutionize the diagnosis of respiratory tract infections. Its breath collection device enables non-invasive collection of pathogens from breath aerosols and works with existing PCR tests. The novel device is designed for broad utility, similar to other sample collection technologies such as blood tubes.
Comments